The FDA responds to inaccuracies in an opinion piece about direct-to-consumer drug ads, clarifying its role in ensuring truthful and accurate prescription drug promotion. Federal law requires ads to disclose side effects, contraindications, and effectiveness accurately. The FDA issued a final rule establishing standards for presenting major statements in ads to consumers. Companies must comply by 2024. The FDA monitors promotional communications post-marketing to ensure compliance with laws. Jerry Berger and Catherine Estes raise concerns about healthcare industry cybersecurity, suggesting the federal government needs to invest in resources and take a more active role in neutralizing threats. Robert Swaskoski proposes a “Meaningful Use”-like program for provider cyber-preparedness.
Source link
Setting the Record Straight on the FDA’s Authority Over Drug Ads
